Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 3/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | RECQL | P46063 | 1/20 | 0.51 |
| ▸ | EZH2 | Q15910 | 4/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.43 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.43 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.41 |
| ▸ | HRH2 | P25021 | 1/20 | 0.41 |
| ▸ | HRH1 | P35367 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL630660 | 0.83 | TSHR (0.57) | POLBKMT2AMEN1MAPTRECQL | |
| SCHEMBL5169287 | 0.82 | POLB (0.47) | POLBKMT2AMEN1MAPTRECQL | |
| SCHEMBL6166782 | 0.80 | POLB (0.62) | POLBKMT2AEZH2TSHRPKM | |
| SCHEMBL17800950 | 0.78 | POLB (0.57) | POLBKMT2AMEN1MAPTRECQL | |
| SCHEMBL25060205 | 0.78 | POLB (0.57) | POLBKMT2AMEN1MAPTRECQL | |
| Hydrochloric Acid SCHEMBL16816653 | 0.77 | ITGB3 (0.53) | ITGB3ITGA2B | |
| Hydrochloric Acid SCHEMBL16816654 | 0.77 | ITGB3 (0.53) | ITGB3ITGA2B | |
| SCHEMBL631683 | 0.74 | MEN1 (0.45) | POLBKMT2AMEN1MAPTRECQL | |
| SCHEMBL25060405 | 0.73 | POLB (0.46) | POLBKMT2AMEN1MAPTRECQL | |
| SCHEMBL630382 | 0.72 | ACACB (0.50) | ITGB3ITGA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1778637-B1 | FKBP-binding composition and pharmaceutical use thereof | AVENTIS PHARMA INC (US) | 2012-02-22 | — | — | EP | claimed |
| US-7777042-B2 | N-sulfonylpipecolic acid derivative FKBP binding composition and pharmaceutical use thereof | AVENTIS PHARMACEUTICALS INC. (US) | 2010-08-17 | — | — | US | claimed |
| US-20080139556-A1 | FKBP BINDING COMPOSITION AND PHARMACEUTICAL USE THEREOF | AVENTIS PHARMACEUTICALS INC. (US) | 2008-06-12 | — | — | US | claimed |
| US-7777042-B2 | N-sulfonylpipecolic acid derivative FKBP binding composition and pharmaceutical use thereof | AVENTIS PHARMACEUTICALS INC. (US) | 2010-08-17 | — | — | US | disclosed |
| US-20080139556-A1 | FKBP BINDING COMPOSITION AND PHARMACEUTICAL USE THEREOF | AVENTIS PHARMACEUTICALS INC. (US) | 2008-06-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080139556-A1 | FKBP BINDING COMPOSITION AND PHARMACEUTICAL USE THEREOF | FKBP1A, FKBP1B, FKBP3 | POLB 4105/4885KMT2A 4807/4885MEN1 4809/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.